ClinicalTrials.gg
CompletedNCT01181622REACH-1Updated Jan 13, 2015

A Safety and Tolerability Study of Denufosol in 2-4 Year Olds

A Phase 2 interventional study of denufosol tetrasodium Inhalation Solution and 0.9% w/v sodium chloride solution in Cystic Fibrosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2015-01-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
2 Years to 4 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cystic Fibrosis by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Merck & Co., Inc.

Enrollment
7th of 10
25 · median 68
Started
2010
the only one that year
Phase 2
6 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 6 in phase 2, and was the 9th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 10 studies in Cystic Fibrosis by Merck & Co., Inc is open now. The open studies under Cystic Fibrosis, anywhere →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 2 Years to 4 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Cystic Fibrosis by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of denufosol 60 mg TID in pediatric CF patients 2 to 4 years of age

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of CF
  • Have oxyhemoglobin saturation ≥ 95% prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Have acute intercurrent respiratory infection (cough, wheezing, or new

rhinorrhea or nasal congestion)

  • Have any significant medical condition not related to CF
  • Unable to discontinue use of hypertonic saline
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    denufosol tetrasodium Inhalation Solution

    Drug: denufosol tetrasodium Inhalation Solution

  • Placebo comparator
    Placebo

    Drug: 0.9% w/v sodium chloride solution

Interventions

  • Drugdenufosol tetrasodium Inhalation Solution

    60 mg by oral inhalation three times daily

  • Drug0.9% w/v sodium chloride solution

    0.9% w/v sodium chloride solution by oral inhalation three times daily

06

What researchers measure

Primary outcomes

  1. Intolerability to study drug as measured by: oxyhemoglobin saturation, treatment-emergent cough, and new wheezes or crackles

    Time frame: Day 1, Day 7

Secondary outcomes

  1. Mean change from pre-dose in oxyhemoglobin saturation at defined times post-dose

    Time frame: Day 1, Day 7

  2. Mean change from baseline in oxyhemoglobin saturation

    Time frame: Day 7

  3. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and/or withdrawals due to TEAEs

    Time frame: Day 7

  4. Mean change from pre-dose in pulse and respiratory rate at defined times post-dose

    Time frame: Day 1, Day 7

  5. Mean change from baseline in pulse and respiratory rate

    Time frame: Day 7

  6. Incidence of new medical condition(s) or worsening of previous medical condition(s) from baseline

    Time frame: Day 7

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2010
First posted
Aug 13, 2010
Start
Aug 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results delay requested
Mar 24, 2011
Last update
Jan 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01181622
Responsible party
Sponsor
First posted
Aug 13, 2010
Start date
Aug 2010
Primary completion
Oct 2010
Completion
Oct 2010
Last update
Jan 13, 2015

Study contacts

Lynn Smiley, MD
study director · Medical monitor

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion